- United Kingdom
- /
- Medical Equipment
- /
- AIM:SPEC
A Look At The Intrinsic Value Of INSPECS Group plc (LON:SPEC)
Key Insights
- INSPECS Group's estimated fair value is UK£0.87 based on 2 Stage Free Cash Flow to Equity
- With UK£0.70 share price, INSPECS Group appears to be trading close to its estimated fair value
- INSPECS Group's peers seem to be trading at a higher discount to fair value based onthe industry average of 45%
How far off is INSPECS Group plc (LON:SPEC) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by estimating the company's future cash flows and discounting them to their present value. We will use the Discounted Cash Flow (DCF) model on this occasion. Believe it or not, it's not too difficult to follow, as you'll see from our example!
We generally believe that a company's value is the present value of all of the cash it will generate in the future. However, a DCF is just one valuation metric among many, and it is not without flaws. For those who are keen learners of equity analysis, the Simply Wall St analysis model here may be something of interest to you.
View our latest analysis for INSPECS Group
The Model
We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. To begin with, we have to get estimates of the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we discount the value of these future cash flows to their estimated value in today's dollars:
10-year free cash flow (FCF) forecast
2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | |
Levered FCF (£, Millions) | UK£3.70m | UK£5.80m | UK£6.34m | UK£6.77m | UK£7.12m | UK£7.41m | UK£7.66m | UK£7.86m | UK£8.04m | UK£8.21m |
Growth Rate Estimate Source | Analyst x1 | Analyst x1 | Est @ 9.23% | Est @ 6.87% | Est @ 5.22% | Est @ 4.07% | Est @ 3.26% | Est @ 2.70% | Est @ 2.30% | Est @ 2.03% |
Present Value (£, Millions) Discounted @ 9.0% | UK£3.4 | UK£4.9 | UK£4.9 | UK£4.8 | UK£4.6 | UK£4.4 | UK£4.2 | UK£4.0 | UK£3.7 | UK£3.5 |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = UK£42m
We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (1.4%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 9.0%.
Terminal Value (TV)= FCF2033 × (1 + g) ÷ (r – g) = UK£8.2m× (1 + 1.4%) ÷ (9.0%– 1.4%) = UK£110m
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= UK£110m÷ ( 1 + 9.0%)10= UK£47m
The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is UK£89m. In the final step we divide the equity value by the number of shares outstanding. Relative to the current share price of UK£0.7, the company appears about fair value at a 20% discount to where the stock price trades currently. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent.
Important Assumptions
Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at INSPECS Group as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 9.0%, which is based on a levered beta of 1.282. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for INSPECS Group
- Net debt to equity ratio below 40%.
- No major weaknesses identified for SPEC.
- Expected to breakeven next year.
- Has sufficient cash runway for more than 3 years based on current free cash flows.
- Good value based on P/S ratio and estimated fair value.
- Debt is not well covered by operating cash flow.
Looking Ahead:
Valuation is only one side of the coin in terms of building your investment thesis, and it ideally won't be the sole piece of analysis you scrutinize for a company. The DCF model is not a perfect stock valuation tool. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. For INSPECS Group, there are three pertinent aspects you should assess:
- Risks: As an example, we've found 1 warning sign for INSPECS Group that you need to consider before investing here.
- Future Earnings: How does SPEC's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!
PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the AIM every day. If you want to find the calculation for other stocks just search here.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About AIM:SPEC
INSPECS Group
Designs, produces, sells, markets, and distributes fashion eyewear, lenses, and OEM products worldwide.
Flawless balance sheet and undervalued.